Should I buy or sell IDEAYA Biosciences stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares. View IDYA analyst ratings or view top-rated stocks .

What is IDEAYA Biosciences' stock price target for 2024?

13 analysts have issued 12 month target prices for IDEAYA Biosciences' stock. Their IDYA share price targets range from $24.00 to $60.00. On average, they expect the company's share price to reach $44.55 in the next year. This suggests a possible upside of 20.0% from the stock's current price. View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts .

How have IDYA shares performed in 2024?

IDEAYA Biosciences' stock was trading at $35.58 at the start of the year. Since then, IDYA shares have increased by 4.4% and is now trading at $37.13. View the best growth stocks for 2024 here .

Are investors shorting IDEAYA Biosciences?

IDEAYA Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Based on an average trading volume of 905,000 shares, the days-to-cover ratio is currently 10.4 days. Approximately 14.3% of the company's stock are sold short. View IDEAYA Biosciences' Short Interest .

When is IDEAYA Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our IDYA earnings forecast .

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05. The business had revenue of $3.90 million for the quarter, compared to analyst estimates of $8.84 million. IDEAYA Biosciences had a negative trailing twelve-month return on equity of 23.00% and a negative net margin of 483.05%. The firm's revenue was down 3.0% compared to the same quarter last year.

What ETFs hold IDEAYA Biosciences' stock?

ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , ALPS Medical Breakthroughs ETF (SBIO) , Jacob Forward ETF (JFWD) , Range Cancer Therapeutics ETF (CNCR) , Loncar China Biopharma ETF (CHNA) , SPDR S&P Biotech ETF (XBI) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) .

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX) , Fulcrum Therapeutics (FULC) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Boeing (BA) , Xeris Biopharma (XERS) , Entasis Therapeutics (ETTX) , Livongo Health (LVGO) and NVIDIA (NVDA) .

When did IDEAYA Biosciences IPO?

IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include JTC Employer Solutions Trustee Ltd (0.00%). Insiders that own company stock include Briseno Andres Ruiz , Jason Throne , Michael P Dillon, Michael P Dillon , Paul A Stone and Yujiro S Hata . View institutional ownership trends .

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:IDYA

IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

→ Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad)

Free IDYA Stock Alerts

$37.13

-0.49 (-1.30%)

(As of 04/19/2024 ET)

Compare

Today's Range: $36.58
▼
$38.30
50-Day Range: $37.13
▼
$47.13
52-Week Range: $14.33
▼
$47.74

Volume: 726,233 shs
Average Volume: 524,372 shs
Market Capitalization: $2.77 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.55

Get IDEAYA Biosciences alerts:

IDEAYA Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 20.0% Upside
$44.55 Price Target
Short Interest: Bearish
14.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.79
Upright™ Environmental Score
News Sentiment: 0.75
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1.25 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.26) to ($2.63) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.47 out of 5 stars

Medical Sector

271st out of 911 stocks

Pharmaceutical Preparations Industry

114th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
IDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
IDEAYA Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
14.29% of the float of IDEAYA Biosciences has been sold short.
Short Interest Ratio / Days to Cover
IDEAYA Biosciences has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
Change versus previous month
Short interest in IDEAYA Biosciences has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
IDEAYA Biosciences does not currently pay a dividend.
Dividend Growth
IDEAYA Biosciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEAYA Biosciences has received a 72.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEAYA Biosciences is -0.79.

2.6

News and Social Media Coverage

News Sentiment
IDEAYA Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for IDEAYA Biosciences this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,248,886.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of IDEAYA Biosciences is held by insiders.
Percentage Held by Institutions
98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.26) to ($2.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEAYA Biosciences is -18.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEAYA Biosciences is -18.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IDEAYA Biosciences has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

About IDEAYA Biosciences Stock (NASDAQ:IDYA)

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDYA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IDYA Stock News Headlines

April 18, 2024 | americanbankingnews.com

Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Increases By 6.7%

April 10, 2024 | americanbankingnews.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Buy" from Analysts

April 20, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

April 5, 2024 | prnewswire.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 1, 2024 | prnewswire.com

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

March 20, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - IDYA

March 13, 2024 | markets.businessinsider.com

Strong Buy Rating for IDEAYA Biosciences Based on Strategic Partnership and Promising Oncology Pipeline

March 12, 2024 | seekingalpha.com

Ideaya inks clinical trial pact with Merck

April 20, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

March 12, 2024 | msn.com

Ideaya gains after clinical trial pact with Merck

March 12, 2024 | markets.businessinsider.com

IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial Cancer

March 12, 2024 | prnewswire.com

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

March 10, 2024 | benzinga.com

IDEAYA Biosciences Stock (NASDAQ:IDYA), Quotes and News Summary

March 8, 2024 | markets.businessinsider.com

Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews

March 4, 2024 | prnewswire.com

IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events

February 26, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD)

February 24, 2024 | msn.com

IDEAYA Biosciences (IDYA) Price Target Increased by 28.90% to 51.57

February 23, 2024 | finance.yahoo.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results

February 21, 2024 | markets.businessinsider.com

The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts

February 20, 2024 | realmoney.thestreet.com

Ideaya Biosciences price target raised by $10 at Oppenheimer, here's why

February 20, 2024 | benzinga.com

Recap: IDEAYA Biosciences Q4 Earnings

February 20, 2024 | markets.businessinsider.com

IDEAYA Biosciences Q4 Results Misses Estimates

February 20, 2024 | finance.yahoo.com

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 20, 2024 | prnewswire.com

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 16, 2024 | seekingalpha.com

Ideaya Biosciences: A Strong Bet In Targeted Oncology

February 15, 2024 | finance.yahoo.com

IDYA Apr 2024 35.000 put

February 15, 2024 | finance.yahoo.com

IDYA Apr 2024 45.000 put

See More Headlines

Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IDYA
CUSIP: N/A
CIK: 1676725
Web: www.ideayabio.com
Phone: (650) 443-6209
Fax: N/A
Employees: 124
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $44.55
High Stock Price Target: $60.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +20.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,960,000.00
Net Margins: -483.05%
Pretax Margin: -483.05%
Return on Equity: -23.00%
Return on Assets: -21.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.65
Quick Ratio: 19.65

Sales & Book Value

Annual Sales: $23.39 million
Price / Sales: 118.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.64 per share
Price / Book: 3.85

Miscellaneous

Outstanding Shares: 74,560,000
Free Float: 70,757,000
Market Cap: $2.77 billion
Optionable: Optionable
Beta: 0.80

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Yujiro S. Hata (Age 50)
President, CEO & Director
Comp: $851.7k
Dr. Michael A. White Ph.D. (Age 58)
Chief Scientific Officer
Comp: $613.85k
Dr. Darrin M. Beaupre M.D. (Age 57)
Ph.D., Chief Medical Officer
Comp: $152.64k
Mr. Andres Ruiz Briseno CPA (Age 37)
Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations
Dr. Paul A. Barsanti Ph.D.
Chief Technology Officer
Mr. Jason S. Throne Esq. (Age 52)
J.D., Chief Legal Officer & Company Secretary
Comp: $425.56k
Mr. Mick O'Quigley
Chief of Staff & Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IDYA Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings or view top-rated stocks.
What is IDEAYA Biosciences' stock price target for 2024?: 13 analysts have issued 12 month target prices for IDEAYA Biosciences' stock. Their IDYA share price targets range from $24.00 to $60.00. On average, they expect the company's share price to reach $44.55 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts.
How have IDYA shares performed in 2024?: IDEAYA Biosciences' stock was trading at $35.58 at the start of the year. Since then, IDYA shares have increased by 4.4% and is now trading at $37.13.
View the best growth stocks for 2024 here.
Are investors shorting IDEAYA Biosciences?: IDEAYA Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Based on an average trading volume of 905,000 shares, the days-to-cover ratio is currently 10.4 days. Approximately 14.3% of the company's stock are sold short.
View IDEAYA Biosciences' Short Interest.
When is IDEAYA Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our IDYA earnings forecast.
How were IDEAYA Biosciences' earnings last quarter?: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05. The business had revenue of $3.90 million for the quarter, compared to analyst estimates of $8.84 million. IDEAYA Biosciences had a negative trailing twelve-month return on equity of 23.00% and a negative net margin of 483.05%. The firm's revenue was down 3.0% compared to the same quarter last year.

What ETFs hold IDEAYA Biosciences' stock?: ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Jacob Forward ETF (JFWD), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).
What other stocks do shareholders of IDEAYA Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).
When did IDEAYA Biosciences IPO?: IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.
Who are IDEAYA Biosciences' major shareholders?: IDEAYA Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include JTC Employer Solutions Trustee Ltd (0.00%). Insiders that own company stock include Briseno Andres Ruiz, Jason Throne, Michael P Dillon, Michael P Dillon, Paul A Stone and Yujiro S Hata.
View institutional ownership trends.
How do I buy shares of IDEAYA Biosciences?: Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDYA) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial